Mereo BioPharma (MREO) Net Cash Flow (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Net Cash Flow of -$4.6 million for Q1 2026, up 43.94% year-over-year from -$3.2 million in Q1 2025, and up 39.66% quarter-over-quarter from -$7.6 million in Q4 2025.
Mereo BioPharma (MREO) Net Cash Flow (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Net Cash Flow for 4 consecutive years, with -$4.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 43.94% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at -$27.0 million (down 306.83% YoY), while the FY2025 annual figure was -$30.7 million, down 343.09% from the prior year.
- Net Cash Flow rose to -$4.6 million in Q1 2026 per MREO's latest filing, from -$7.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $38.9 million in Q2 2024 and bottomed at -$9.7 million in Q1 2023.
- Historically, Net Cash Flow has averaged -$2.4 million across 4 years, with a median of -$7.7 million in 2025.
- Annual changes were most pronounced in 2024 — Net Cash Flow tumbled 176.79% — and 2026, when it surged 43.94%.
- Mereo BioPharma's Net Cash Flow stood at -$6.8 million in 2023, then tumbled by 39.34% to -$9.5 million in 2024, then rose by 19.21% to -$7.6 million in 2025, then soared by 39.66% to -$4.6 million in 2026.
- Business Quant data shows MREO's Net Cash Flow at -$4.6 million in Q1 2026, -$7.6 million in Q4 2025, and -$7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | -6.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.04 Mn |
| Jun 30, 2026 | -6.04 Mn |
| Mar 31, 2026 | -4.61 Mn |
| Mar 31, 2026 | -4.61 Mn |
| Dec 31, 2025 | -7.64 Mn |
| Dec 31, 2025 | -7.64 Mn |
| Sep 30, 2025 | -7.01 Mn |
| Sep 30, 2025 | -7.01 Mn |
| Jun 30, 2025 | -7.79 Mn |
| Jun 30, 2025 | -7.79 Mn |
| Mar 31, 2025 | -8.23 Mn |
| Mar 31, 2025 | -8.23 Mn |
| Dec 31, 2024 | -9.46 Mn |
| Dec 31, 2024 | -9.46 Mn |
| Sep 30, 2024 | -8.11 Mn |
| Sep 30, 2024 | -8.11 Mn |
| Jun 30, 2024 | 38.88 Mn |
| Jun 30, 2024 | 38.88 Mn |
| Mar 31, 2024 | -8.69 Mn |
| Mar 31, 2024 | -8.69 Mn |